Publication

Article

CURE

Fall 2009
Volume8
Issue 3

Overheated

Author(s):

Cooling hot flashes brought on by cancer treatments.

Hot flashes are experienced by both men and women when cancer or its treatment affects hormone levels, but there are ways to manage hot flashes that can improve a patient’s quality of life.

When hormone levels fluctuate or dip below normal, a patient can experience very warm sensations in the upper chest and face, flushing, and sweating that can last from a few moments up to 30 minutes. The severity, frequency, and duration of hot flashes vary depending on the patient’s age, cancer type, and treatment, among other factors.

Hot flashes tend to be more problematic for breast cancer patients and survivors than for women in general, says Charles Loprinzi, MD, a medical oncologist at Mayo Clinic Cancer Center in Rochester, Minnesota, because giving chemotherapy to premenopausal women can make their ovaries turn off rather abruptly. “And if women have an abrupt menopause, an abrupt decrease of estrogen, it usually causes more trouble with hot flashes than if they more gradually go through menopause.”

Hot flashes can occur in breast and gynecologic cancer patients whose ovaries are removed as part of treatment as well as breast cancer patients who receive hormonal therapies—specifically tamoxifen, which blocks the effects of estrogen, and aromatase inhibitors, which further lower already low estrogen levels in postmenopausal women.

As for prostate cancer, rapidly taking away testosterone with surgery or hormonal therapies, such as Lupron Depot (leuprolide) and Zoladex (goserelin), that deprive prostate cancer cells of androgen hormones (including testosterone) can cause hot flashes similar to what women experience during menopause, Loprinzi says.

Hot flashes can also result from radiation therapy to the pelvic area, which may damage ovarian and testis tissue and decrease hormone levels.

Most treatments that reduce hot flashes work equally well in men and women.

Hormone replacement therapy can significantly reduce hot flashes in women, but estrogen formulations are not recommended for women with a history of breast cancer because they may spur tumor growth. Replacing testosterone in men will resolve hot flashes, but that defeats the purpose of testosterone-reduction therapy for treating prostate cancer.

The blood pressure medication Catapres (clonidine) decreases hot flashes 10 to 15 percent more than a placebo, Loprinzi says, although the drug appears to be less effective in men compared with women. He adds that newer antidepressants known as serotonin and norepinephrine reuptake inhibitors (SNRIs), such as Effexor (venlafaxine), may work even better. “This drug decreases hot flashes by about 50 to 60 percent.”

Another type of antidepressant, selective serotonin reuptake inhibitors (SSRIs), such as Paxil (paroxetine) and Prozac (fluoxetine), can reduce hot flashes, but new research shows some SSRIs can interfere with the activity of tamoxifen, making it less effective.

Several placebo-controlled studies have shown that Neurontin (gabapentin), a drug used to treat seizures and nerve pain associated with peripheral neuropathy, also reduces hot flashes by up to 60 percent in both men and women.

Studies of integrative therapies are ongoing and new data suggest flax seed may be helpful in treating hot flashes, Loprinzi says.

Simple lifestyle changes may help reduce the severity of hot flashes. Experts recommend trying to avoid circumstances or activities that may trigger hot flashes. Stress is a frequent trigger, so practicing stress-reduction techniques, such as meditation or yoga, may be helpful. Other suggestions include wearing lightweight cotton clothing and sleepwear, staying hydrated, and avoiding alcohol, caffeine, and spicy foods.

Related Videos
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine in the Department of Medicine at Beth Israel Deaconess Medical Center in Boston.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Image of man with brown and grey hair.
Image of a woman with light shoulder-length hair, wearing rectangular glasses.
Related Content